Setipiprant is an investigational drug developed for the treatment of asthma and scalp hair loss. It was originally developed by Actelion and acts as a selective, orally available antagonist of the prostaglandin D2 receptor 2 (DP2). The drug is being developed as a novel treatment for male pattern baldness by Allergan. Reference standards of Setipiprant API,and its pharmacopeial, non pharmacopeial impurities, and stable isotopes are listed below.
stdClass Object ( [pname] => Setipiprant-API [catalogue_number] => PA 19 1600000 [category_ids] => ,75,76,78,70,82, [chemical_name] => [weight] => 402.43 [form] => C24H19FN2O3 [cas] => 866460-33-5 [pslug] => 866460-33-5-setipiprant-api-pa191600000 [latest_product] => 0 [linkproducts] => 0 [offers_id] => [offers_name] => [offers_status] => [offers_start_date] => [offers_end_date] => [pageview] => [offers_slug] => [offers_product_id] => [offers_product_code] => [offers_master_id] => [offer_percentage] => [offers_product_main_cat] => )
Catalogue No.:PA 19 1600000
CAS :
Molecular Formula : C24H19FN2O3
Molecular Weight : 402.43
I accept terms and conditions
Message sent successfully!! We will get back to you shortly ....
